| Click icon to automatically deliver podcasts to your iTunes or rich media player.
|
|
 |
What’s the best managed pharma? Each year, Professor Bill Trombetta of Saint Joseph’s University attempts to answer the question in Pharm Exec’s “Industry Audit”, applying a battery of traditional and nontraditional metrics to the largest publicly held companies.
This year, in addition to his article, Bill agreed to sit down with editor-in-chief Patrick Clinton for a conversation on the top four companies and what makes them special. |
|
 | Professor Bill Trombetta, of Saint Joseph’s University discusses his annual Industry Audit. | | Podcast #1 (18:15) | | | How to measure a pharma company If you want to want to truly understand how well a company is performing, you need to get past the basics of revenue, profit margin, and price earnings ratio. In this episode, Bill Trombetta explains which metrics really get at the heart of good pharma management. |
| | | Podcast #2 (11:16) | | | Eli Lilly: With double-digit growth in sales, and a solid improvement in revenue per employee, Lilly placed fourth in the Company of the Year rundown. Bill Trombetta explains Lilly’s position as a big/small pharma and maps out the challenges that lie ahead for Lilly. |
|
| | | Podcast #3 (12:36) | | | Johnson & Johnson: A perennial member of the Top Four, J&J defies the conventional wisdom; it’s a big company that still manages to grow, a sprawling, diversified company that still has focus. And along with just three other companies on our list, it created shareholder value in 2007. Bill Trombetta explains how. |
|
|
| | | Podcast #4 (10:56) | | | Genentech: Another permanent resident on the Top Four list, Genentech turns in mind-bending numbers. The big question: can Genentech keep it up. Bill Trombetta looks at the original biotech’s remarkable successes and its challenges. |
| | | Podcast #5 (15:40) | | | Biogen Idec: “This was Biogen’s year,” says Professor Bill Trombetta. In this episode, Bill spotlights some of the company’s achievements, including an all-star performance at simultaneously managing assets and margins, then explores some ways in which companies need to re-envision their roles to be successful in tomorrow’s market. |
|
|
 |
 |
 |
| Pharm Exec scoured the industry and awarded 45 executives with its Emerging Leadership Award. Listen to interviews with 14 of these “Change Generation” executives who are helping the pharma industry to reinvent itself for the 21st century. |
|
|
 | Want to know how to market in today’s resource-constrained environment? Tariq Arshad, MD, senior manager of worldwide commercial development for Pfizer, said that starting his career in Pakistan taught him everything he needed to know. | | 10:02 Minutes | | |
|
|
|
 | Michael Burke, chief commercial officer for Ovation Pharmaceuticals, talks about the difference leadership makes in the specialty space. | | 12:28 Minutes | | |
|
|
|
 | Barry Greene, President and COO of the RNAi powerhouse Alnylam, traces his rise to the top through mentors and medicine. | | 10:48 Minutes | | |
|
|
|
 | Martin Jernigan, associate vice president of Novo Nordisk’s liraglutides launch, talks about how to merge science and commercialization on an organizational level. | | 10:04 Minutes | | |
|
|
|
 | Leadership is about making courageous and clear decisions, says Sean McLoughlin, product director of GlaxoSmithKline’s diabetes franchise, which can be different for pharma’s growing number of customers. | | 6:27 Minutes | | |
|
|
|
 | Innovation hasn’t survived in Big Pharma, says Adnan Mjalli, founder, president, and CEO of TransTech Pharma. But bringing science back into the C-suite could help. | | 13:19 Minutes | | |
|
|
|
 | Angela Moskow, vice president of diabetes marketing for Sanofi-Aventis, reflects on her career-long focus on diabetes, and offers some leadership tips she’s picked up along the way. | | 8:11 Minutes | | |
|
|
|
 | How does a physician come to join the pharma industry? There’s no roadmap, says Wendy Niebler, DO, vice president of global medical affairs of ADHD for Shire Pharmaceuticals, but you can still make an impact on patients. | | 8:13 Minutes | | |
|
|
|
 | If companies are going to create best-in-class drugs, that work needs to start early in development, says Rich Tillyer, senior vice president, worldwide preclinical development for Merck. In this podcast, Tillyer traces his career at Merck and talks about the importance of providing scientists with the space to innovate. | | 11:03 Minutes | | |
|
|
|
 | Life didn’t start easy for Hoji Alimi, Founder, President, and CEO of Oculus Innovative Sciences, who was exhiled from Iran as a teenager. But conviction in a compound which some have even called miracle, pointed the path toward success. | | 15:25 Minutes | | |
|
|
|
 | Cameron Durrant, Johnson & Johnson’s worldwide vice president, virology global strategic marketing, tears up tradition and tells how visionary thinking can bring new leadership and instill more value in pharma. | | 11:32 Minutes | | |
|
|
|
 | Merck’s executive director of portfolio strategy and strategic planning, Blair Gibson, takes a deep dive into resource allocation and the new way to view pharma’s business. | | 10:53 Minutes | | |
|
|
|
 | Erik Harris, senior director of sales and marketing of Tysabri for Elan, talks about the challenges in marketing the drug and the leadership philosophy that paves the way. | | 12:24 Minutes | | |
|
|
|
 | Nancy Phelan, executive director of consumer communications and e-marketing for Wyeth, talks about perfecting DTC advertising in an imperfect world. | | 9:44 Minutes | | |
|
|
|
| |
